Reports Q4 revenue $173.3M, consensus $170.43M. “We were very pleased with the overall execution on our transformation initiative last year, which sets the foundation for more profitable growth in 2024 and for reaching our mid-term financial targets in 2025,” said Joe Woody, Avanos’s chief executive officer. Woody continued, “We believe we are poised to maintain the positive momentum in our Digestive Health portfolio and we are also confident that our strategy for the Pain Management and Recovery business will lead to sustainable growth as we enter 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVNS:
- Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2023 Results
- Avanos falls -13.5%
- Avanos falls -11.6%
- Avanos sees FY24 revenue $685M-$705M, consensus $714.43M
- Avanos Medical, Inc. Reports Preliminary Fourth Quarter and Full-Year 2023 Financial Results; Revises Preliminary 2024 Revenue Outlook
